



CENTER FOR MEDICARE

DATE: July 22, 2022

TO: All Prescription Drug Plans, Medicare Advantage-Prescription Drug Plans, Section 1876 Cost Plans, Medicare-Medicaid Plans, and PACE Organizations

FROM: Amy Larrick Chavez-Valdez
Director, Medicare Drug Benefit and C & D Data Group

SUBJECT: Summer Update Window for CY 2023 Formularies

CMS is currently granting conditional approvals for CY 2023 formularies and is in the process of contacting those organizations that still have outstanding formulary issues. CMS reminds all Part D sponsors of the importance of resolving any outstanding formulary concerns in an expeditious manner.

Formularies that are in an approved status within the Health Plan Management System (HPMS) will be eligible for updating during the summer update window. Part D sponsors will have the opportunity to make limited updates, as outlined below, to their conditionally approved CY 2023 formulary submissions from **12:00 a.m. EDT August 4, 2022 through 5:00 p.m. EDT August 8, 2022**. A revised CY 2023 Formulary Reference File (FRF) and accompanying change report are available within the CY 2023 HPMS Formulary Submission Module.

During the summer update window, Part D sponsors will be permitted to make the following changes to previously approved CY 2023 formularies:

1. Addition of drugs new to the updated CY 2023 FRF;¹
2. Negative changes to an existing formulary drug, if an equivalent generic or therapeutically similar drug is available on the FRF and is submitted on the corresponding formulary file update within the same category and class, at the same or lower cost share tier, and with no more restrictive utilization management (UM) than what was applied to the existing formulary drug;
3. Other limited formulary enhancements (e.g., formulary additions, reduction in cost share tier, removal of utilization management edits).

¹ New protected class drugs on the FRF must be added during this submission window.

We do not expect sponsors to make significant formulary enhancements or significant negative changes during this window, as the formulary that was initially submitted to CMS for review was used to develop the Part D bid.

Revisions to existing utilization management criteria should be limited to Step Therapy (ST) criteria changes that are necessary as a result of allowable formulary changes described in this memo. ST criteria may only be updated when the addition of a new drug(s) to an existing ST group description necessitates wording changes within the ST Criteria field. In this case, sponsors should submit a PA/ST Criteria Change Request File via HPMS between 12:00 a.m. EDT August 1, 2022 and 5:00 p.m. EDT on August 3, 2022. Please refer to the HPMS Formulary Submission Module & Reports Technical Manual for detailed submission instructions:

HPMS Homepage > Plan Formularies > Formulary Submission Module > CY 2023 > Documentation > Formulary Instructions

Following the update window, Part D sponsors should check the status of formulary approvals in HPMS. Approval of formulary updates will be entered into HPMS by August 23, 2022. If you have any questions regarding this summer update window, please email PartDFormularies@cms.hhs.gov.